Trial Profile

A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tislelizumab (Primary)
Indications Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Extranodal NK-T-cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; Sezary syndrome; T-cell lymphoma
Focus Therapeutic Use
Sponsors BeiGene

Most Recent Events

17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association
07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
25 Mar 2022 Number of treatment arms have been increased from 1 to 3 by the addition of separate experimental cohort arms as- Cohort 1: ENKTL, Cohort 2: PTCL-NOS, AITL, and ALCL and Cohort 3: MF and SS.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com